| |
NEW YORK, Nov 5 (Reuters) - ImClone Systems Inc said it has acquired exclusive rights to a recently discovered protein, which may play an important role in the early growth of cancers.
This protein, referred to as VE-cadherin-2, is believed to enable the formation of a capillary blood vessel network in solid tumors, an essential step in the uncontrolled growth of malignancies, the company said Wednesday.
The rights to the protein were acquired from Elisabetta Dejana, the person who discovered it.
ImClone Systems is developing antagonists to VE-cadherin-2 to inhibit tumor vascularization.
The company said it also initiated a collaboration with Mario Negri Institute (Milan, Italy) to conduct pharmacological research in Dejana's laboratory on the role of VE-cadherin-2 in angiogenesis.
REUTERS
19:54 11-06-97
|
|
